Zimbabwe has rejected a substantial US healthcare agreement worth $367m (272 million pounds) spanning five years because of Washington's insistence on sensitive data.
This rejection was revealed following a official document dated December was disclosed, which showed President Emmerson Mnangagwa believed the arrangement was "lopsided".
A government representative later explained that the United States was requesting genetic material for research and commercial purposes while was unwilling to share the resulting advantages from future vaccines.
"We will now turn to the difficult and regrettable process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for more negotiations to find a deal agreeable to all parties so the country's critical HIV programme can continue.
Wider Implications
Zimbabwe's decision comes after a similar case in Kenya, where a high court halted a related health funding agreement after concerns were filed about the safety of citizens' health data.
Since resuming office recently, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump argued its expenditure was "inefficient" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
Based on reports, Sixteen nations in Africa have so far signed these new agreements, constituting more than $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, with no equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that could result from that shared data," he stated.
"Effectively, our nation would provide the basic resources for medical research with no assurance that the final treatments would be available to our citizens should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining systems already established via the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to deal with potential global health emergencies.
"This mechanism is intended to ensure that when a country provides its information, the resulting advantages – including medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to create them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how subsequent co-operation could be arranged in a manner that honours the independence and interests of both nations."
Health Experts Reaction
Medical experts said it acknowledged the government's concerns, but suggested that talks need to persist since a large portion of the country's Aids initiatives were funded by international support.
"If technical issues arise, including those involving data governance or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," it added.
This impasse highlights the ongoing debate between accepting crucial international aid and safeguarding local interests in an increasingly data-driven world.